MedTrace Logo

Hypertension in Breast Cancer Patients Receiving Bevacizumab

NCT00674011 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2014-05-06

No results posted yet for this study

Summary

This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, starving the tumor of nutrients and oxygen. Previous studies have shown these types of drugs can cause hypertension. The purpose of this study is to help researchers better understand why these drugs cause hypertension. This information will assist researchers in learning how to control this side effect.

Conditions

Interventions

DRUG

Bevacizumab

Given as part of standard of care or another research protocol

Sponsors & Collaborators

Principal Investigators

  • Erica Mayer, MD MPH · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674011 on ClinicalTrials.gov